The causes and consequences of tumour evolution and heterogeneity - European Medical Journal

Continue

The causes and consequences of tumour evolution and heterogeneity

Oncology
At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, reviews the emerging understanding of mutational drivers of tumour heterogeneity, including APOBEC-mediated mutagenesis, that could support the development of future therapeutic strategies.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

We’ve noticed you’re accessing
from North/South America.